{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "LiverTox|HDS in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
M017
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02069106: Phase 4 Interventional Withdrawn Mixed Hyperlipoproteinemia
(2014)
Source URL:
First approved in 2022
Source:
Dexinling by Shenzhen Deyintang Biotechnology Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Dangsim K-7 by Korea Genetic Pharm Co., Ltd
Source URL:
First approved in 2012
Source:
Dangsim K-7 by Korea Genetic Pharm Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2012
Source:
Green Body by Evercarepharm Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04498013: Phase 4 Interventional Unknown status Mammographic Breast Density
(2020)
Source URL:
First approved in 2010
Source:
Evitex by SCA NuTec
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BTB Plus by SCA NuTec
(2010)
Source URL:
First approved in 2010
Source:
BTB Plus by SCA NuTec
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04656730: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2020)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01628705: Phase 4 Interventional Completed Nutritional and Metabolic Disease
(2007)
Source URL:
First approved in 2009
Source:
Sumaxin Cleansing Pads by Medimetriks Pharmaceuticals, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE